US FDA withdraws controversial 2008 guidance that required sponsors to exclude threshold levels of cardiovascular risk before and after approval; new draft guidelines emphasize duration of exposure and breadth of safety evaluations in more diverse Phase III trial population, consistent with advisory committee recommendations.
The US Food and Drug Administration is favoring longer and broader safety assessments over targeted cardiovascular risk evaluations for new type 2 diabetes drugs.
More than 11 years after a landmark guidance document recommended sponsors of new antidiabetic agents uniformly exclude threshold levels of...